Arthur McGivern is a partner in Goodwin's Technology and Life Sciences groups and a member of its Life Sciences and Capital Markets practices. Mr. McGivern works on a wide variety of public and private securities offerings, mergers and acquisitions, royalty-based financings and other complex transactions in the life sciences sector. He also represents public and private companies in their ongoing corporate matters, including SEC compliance and corporate governance, as well as investment banks, hedge funds and other private investment funds in public securities-related matters.





Mr. McGivern’s recent representations include:
  • Royalty Pharma, a leading investor in pre-approval royalties, in its purchases of royalties in transactions valued at more than $15 billion, including (i) its $3.3 billion acquisition of the Cystic Fibrosis Foundation’s royalties on Vertex Pharmaceuticals’ cystic fibrosis treatments, the largest pharmaceutical royalty purchase ever completed, (ii) its $1.14 billion acquisition of UCLA’s royalties on Xtandi, (iii) synthetic royalty financing totaling more than $3 billion with PTC Therapeutics, BioHaven, Immunomedics, Sanofi and other confidential counterparties, (iv) its acquisition of royalties on worldwide sales of Tysabri® from Perrigo Company plc for $2.2 billion plus potential milestone payments up to $650 million, (v) its $827 million acquisition of Ligand Pharmaceuticals’ royalties on sales of Promacta, and (vi) its $255 million purchase of a partial interest in Agios Pharmaceutical, Inc.’s milestone payments and royalty stream of IDHIFA® (enasidenib) from Celgene Corporation
  • Intellia Therapeutics, a leading genome editing company, in its (i) $15 million Series A financing, (ii) foundational license agreement with Caribou Biosciences pursuant to which Intellia has the right to therapeutic applications of CRISPR/Cas9 technology, (iii) exclusive collaboration and license agreement with Novartis, (iv) exclusive collaboration and license agreement with Regeneron and the 2020 expansion thereof, (v) $70 million Series B financing, (vi) $112 million initial public offering and concurrent $55 million private placements and (vii) follow-on public offerings, raising over $300 million
  • Repligen Corporation, a NASDAQ-listed bioprocessing company, in multiple equity offerings and convertible note offerings raising more than $900 million and in its acquisitions of (i) Novozymes Biopharma’s bioprocessing business, (ii) Refine Technology’s Alternating Tangential Flow (“ATF”) System, (iii) Atoll GmbH, (iv) TangenX, (v) Spectrum Life Sciences and (vi) C Technologies
  • Leading investment banks in connection to Royalty Pharma plc’s $2.5 billion initial public offering
  • Foundation Medicine, a cancer diagnostics company, in (i) a $55 million private financing, (ii) its subsequent $120 million initial public offering on the NASDAQ Stock Market, (iii) its collaboration agreement and equity transaction with Roche, total value in excess of $1 billion, and (iv) its complete acquisition by Roche, which valued Foundation Medicine at $2.4 billion
  • Esperion Therapeutics, a Michigan-based pharmaceutical company developing a treatment for elevated levels of LDL cholesterol, in (i) a $17 million private financing, (ii) its subsequent $80 million initial public offering on the NASDAQ Stock Market, (iii) multiple follow-on public offerings, raising over $450 million, (iv) a licensing transaction with Daiichi Sankyo Europe in which Esperion received $300 million in upfront and near-term milestones, up to $900 million in total milestones and substantial tiered royalties and (v) $200 million royalty-based funding agreement with an investor group led by Oberland Capital
  • AVROBIO, a Phase 2 clinical-stage gene therapy company, in its (i) seed financing with Atlas Ventures, (ii) $25 million and $60 million private financings, (iii) in-license transaction with University Health Network (UHN), (iv) $115 million initial public offering and (v) more than $250 million in follow-on public offerings
  • Karyopharm Therapeutics in a $150 million synthetic royalty financing with HealthCare Royalty Partners
  • eGenesis, a xenotransplantation company using CRISPR gene editing technology, in its $100 million Series B financing
  • Akili Interactive Labs, a prescription digital medicine company, in its (i) $68 million Series C financing and (ii) strategic partnership with Shionogi & Co.
  • Rubius, a biotechnology company pioneering the development of a new class of ready-to-use cellular therapies, in its (i) $120 million Series B financing, (ii) $100 million Series C financing and (iii) $275 million initial public offering
  • Neon Therapeutics, a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, in its (i) $106 million crossover financing, (ii) $100 million initial public offering and (iii) acquisition by BioNtech
  • Aptinyx Inc., a clinical-stage biopharmaceutical company, in its $118 million initial public offering and subsequent follow-on offerings
  • Radius Health, an integrated biopharmaceutical company, in its $300 convertible note financing
  • scPharmaceuticals, a pharmaceutical company, in its (i) $45 million crossover financing, (ii) $95 million initial public offering and (iii) more than $65 million in follow-on offerings
  • Qrativ, developer of a drug purposing platform, in its formation as a joint venture among the Mayo Clinic, Nference and leading investors contributing more than $8 million in Series A financing
  • Agenus Inc., a Lexington, Massachusetts-based biotechnology company focused on immunotherapy including immuno-oncology, in a $230 million royalty financing transaction with HealthCare Royalty Partners, $115 million royalty bond financing transaction with an investor group led by Oberland Capital and $15 million royalty transaction with XOMA Corporation, where XOMA purchased a minority interest in the royalties and milestones that Agenus is eligible to receive from Incyte and Merck
  • H.I.G. BioHealth Partners in its lead investor role in the $22.6 million private financing of Exagen Inc.
  • Guide Medical Ventures in its formation and financing of more than half a dozen portfolio companies
  • Leading investment banks in follow-on public offerings of Sarepta Therapeutics raising more than $700 million
  • JP Morgan and other leading investment banks in (i) the $100 million initial public offering of InflaRx and its subsequent $102 million follow-on offering
  • Credit Suisse and other leading investment banks in the $77 million initial public offering of AC Immune
  • Jefferies and other leading investment banks in the $85 million follow-on public offering of AC Immune
  • The joint bookrunners of the Molecular Partners AG $85.1 million private placement of 5,528,089 registered shares
  • Alnylam Pharmaceuticals, the leading RNAi therapeutics company, in its transformational alliance for the development and commercialization of RNAi therapeutics with Genzyme, a Sanofi company, under which Genzyme purchased $700 million of Alnylam common equity and obtained a series of options to purchase regional (i.e., ex-North America and Western Europe), co-development or global licenses to various Alnylam product candidates
  • Nimbus Therapeutics, developer of computational chemistry platform, in its (i) co-development collaboration with Shire plc which focused on of first-in-class small molecule treatments for several rare genetic diseases, (ii) co-development collaboration with Monsanto which focused on a broad-spectrum fungicides, (iii) private financings, including a $24 million Series A financing and $43 million Series B financing and (iv) sale of its Acetyl-CoA Carboxylase (ACC) inhibitor program to Gilead for $400 million upfront and the potential to receive an additional $800 million
  • SmartCells, Inc., a private biotechnology company developing a glucose responsive insulin, in its capital raising and ongoing operations as well as its ultimate sale to Merck & Co. for an upfront cash payment as well as potential clinical development and regulatory milestones in excess of $500 million and royalties
  • Yumanity Therapeutics, a company focused on discovering transformative therapies to treat neurodegenerative diseases, in more than $100 million in private equity financings, as well as debt financings and its strategic collaboration with Merck
  • Warp Drive Bio, astrategic partnership between Third Rock Ventures and Sanofi, in Warp Drive Bio’s initial $125 million financing and defined collaboration deal, the 2016 extension of this collaboration and Warp Drive’s acquisition by Revolution Medicines
  • CSA Medical, a private medical device company, in its divestment of its commercial truFreeze business to Steris Medical
  • Intellect Medical, a private medical device company developing technologies for deep brain stimulation, in its sale to Boston Scientific in a transaction valued at $78 million
Professional Experience

Prior to joining Goodwin, Mr. McGivern was an associate in the Business Practice Group at Testa, Hurwitz & Thibeault in Boston.


Mr. McGivern has been recognized by The Best Lawyers in America Best Lawyers for his work in Biotechnology and Life Sciences Practice 2022.

Mr. McGivern is consistently recognized in The Best Lawyers in America as a Biotechnology and Life Sciences Practice best lawyer, in the 2019 edition of LMG Life Sciences as a Life Sciences Star in the Corporate, Mergers & Acquisitions category, and in the 2019 edition of The Legal 500 United States for his work in Healthcare: Life Sciences. Mr. McGivern is recognized as member of the Foundation Medicine deal team, which led Goodwin to be recognized by Financial Times (FT) as one of the most innovative law firms in its 2015 North America Innovative Lawyers report.

In The News









J.D., 2004
Boston University School of Law

(cum laude)

B.S.C.E., 1997
Tufts University

(cum laude)



Profile Image
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.


Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Search Other Lawyers
Recherche par Pratique